share_log

BTIG Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $10

Benzinga Real-time News ·  Nov 16, 2022 21:28

BTIG analyst Justin Zelin maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $21 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment